bioRxivMicrobiologyPreprint
A suitable murine model for studying respiratory coronavirus infection and therapeutic countermeasures in BSL-2 laboratories
A. C. d. S. P. Andrade, G. H. Campolina-Silva, C. M. Queiroz-Junior, L. C. de Oliveira, L. d. S. B. Lacerda, J. C. Pimenta, F. R. O. de Souza, I. d. M. Chaves, I. B. Passos, D. C. Teixeira, P. G. Bittencourt-Silva, P. A. C. Valadao, L. Rossi-Oliveira, M. M. Antunes, A. F. A. Figueiredo, N. T. Wnuk, J. R. Temerozo, A. C. Ferreira, A. Cramer, C. A. Oliveira, R. Duraes-Carvalho, C. W. Arns, P. P. G. Guimaraes, G. M. J. Costa, G. B. d. Menezes, , Costa
Abstract
Several animal models are being used to explore important features of COVID-19, nevertheless none of them recapitulates all aspects of the disease in humans. The continuous refinement and development of other options of in vivo models are opportune, especially ones that are carried out at BSL-2 (Biosafety Level 2) laboratories. In this study, we investigated the suitability of the intranasal infection with the murine betacoronavirus MHV-3 to recapitulate multiple aspects of the pathogenesis of COVID-19 in C57BL/6J mice. We demonstrate that MHV-3 replicated in lungs 1 day after inoculation and triggered respiratory inflammation and dysfunction. This MHV-model of infection was further applied to highlight the critical role of TNF in cytokine-mediated coronavirus pathogenesis. Blocking TNF signaling by pharmacological and genetic strategies greatly increased the survival time and reduces lung injury of MHV-3-infected mice. In vitro studies showed that TNF blockage decreased SARS-CoV-2 replication in human epithelial lung cells and resulted in the lower release of IL-6 and IL-8 cytokines beyond TNF itself. Taken together, our results demonstrate that this model of MHV infection in mice is a useful BSL-2 screening platform for evaluating pathogenesis for human coronaviruses infections, such as COVID-19.
- organism: mouse
- research focus: host-pathogen & immune response
- research focus: drug response / drug discovery
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Type I Interferon Limits Viral Dissemination-Driven Clinical Heterogeneity in a Native Murine Betacoronavirus Model of COVID-19
- Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling
B. Goldman-Israelow, E. Song, … A. Iwasaki·bioRxiv·May 27, 2020
- Ivermectin reduces coronavirus infection in vivo: a mouse experimental model
A. P. Arevalo, R. Pagotto, … M. Crispo·bioRxiv·Nov 2, 2020
- The SARS-CoV-2 receptor-binding domain facilitates neutrophil transepithelial migration and nanoparticle uptake in the mice airways
E. L. Bolkhovitina, J. D. Vavilova, … M. A. Shevchenko·bioRxiv·Apr 12, 2022
- Modeling SARS-CoV-2 and Influenza Infections and Antiviral Treatments in Human Lung Epithelial Tissue Equivalents
H. Zarkoob, A. Allue-Guardia, … E. M. Lee·bioRxiv·May 11, 2021
- A novel hamster model of SARS-CoV-2 respiratory infection using a pseudotyped virus
H. Yamada, S. Sasaki, … Y. Morinaga·bioRxiv·Sep 17, 2021